A Phase 1-2 rare rheumatology program achieved all startup milestones ahead of schedule, enrolled eight healthy volunteer cohorts back-to-back on time, and navigated a fundamentally different enrollment landscape when transitioning to patients. The team managed this while adapting to frequent strategy changes and maintaining close sponsor governance across multiple geographies.